Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model: a dose-response study.
The objective of this study was to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) dose on alveolar ridge augmentation and dental implant osseointegration. Bilateral, 5 mm supraalveolar, peri-implant defects were surgically created in 6 beagle dogs. rhBMP-2 (0.05, 0.1 or 0.2 mg/ml) in an absorbable collagen sponge (ACS) carrier was molded around the fixtures and wounds were closed. Treatment variations were alternated between animals (incomplete block design). Animals were sacrificed at week 8 postsurgery. Nine of twelve jaw quadrants healed uneventfully. Two jaw quadrants exhibited wound failure by week 4 and one by week 8 postsurgery. Radiographic bone regeneration was observed in defects without wound failure from week 4 postsurgery. Radiolucent voids of variable size and shape were observed and regressed over time. In weeks 6 through 8, there was an apparent increase in bone density and trabecular structure, while bone height and volume decreased. Histometric analysis revealed limited differences in bone regeneration between experimental conditions. Bone regeneration area averaged (+/- SD) 1.0 +/- 0.5, 3.5 +/- 1.4 and 2.3 +/- 0.4 mm2 for the 0.05, 0.1 and 0.2 mg/ml dose, respectively. There were no significant differences in osseointegration. Osseointegration in newly formed bone averaged 19 +/- 4%, 18 +/- 10% and 21 +/- 6% for the 0.05, 0.1 and 0.2 mg/ml rhBMP-2 sites, respectively. Collectively, the data suggest that there are no dramatic differences in bone induction and osseointegration within the selected dose and observation interval.
Tatakis
Dimitris N
DN
Section of Periodontology, College of Dentistry, The Ohio State University, Columbus 43218-2351, USA.
Koh
Alexander
A
Jin
Lisa
L
Wozney
John M
JM
Rohrer
Michael D
MD
Wikesjö
Ulf M E
UM
D020341:Absorbable Implants; D016301:Alveolar Bone Loss / Q000601:surgery; D000539:Alveolar Process / Q000000981:diagnostic imaging / Q000473:pathology; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D000704:Analysis of Variance; D000818:Animals; D015519:Bone Density / Q000502:physiology; D001853:Bone Marrow / Q000000981:diagnostic imaging / Q000473:pathology; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects / Q000502:physiology*; D002113:Calcification, Physiologic / Q000502:physiology; D003094:Collagen; D003758:Dental Implantation, Endosseous; D015921:Dental Implants; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D006801:Humans; D016348:Osseointegration; D011859:Radiography; D011994:Recombinant Proteins; D013223:Statistics as Topic; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use*; D014945:Wound Healing / Q000502:physiology
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D015921:Dental Implants; D004337:Drug Carriers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D003094:Collagen